NCT00592579CompletedPhase 2
Phase 2, Open-Label, Safety, and Efficacy Study of 2-Methoxyestradiol Administered to Patients With Plateau Phase or Relapsed Multiple Myeloma
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- CASI Pharmaceuticals, Inc.
- Enrollment
- 60
- Locations
- 2
- Primary Endpoint
- To determine tumor response of 2ME2 administered orally by evaluation of objective responses in patients with plateau phase or relapsed multiple myeloma
Study Overview
Brief Summary
The purpose of the study is to determine the safety and effectiveness of providing 2-methoxyestradiol to patients with plateau phase or relapsed multiple myeloma. Information regarding trough 2ME2 levels will also be collected.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Have plateau phase (patients who have been previously treated with at least one conventional or high-dose chemotherapy who are currently off all therapy for at least 4 weeks and are considered to have stable disease) or relapsed MM. Patients in plateau phase must have M-protein concentrations that are stable for at least 4 weeks prior to registration.
- •Be at least 18 years of age.
- •Have monoclonal plasma cells in the marrow.
- •have M-protein greater than or equal to 1g/dL in the serum or 200 mg of monoclonal light chain in a 24-hour urine protein electrophoresis.
- •Have laboratory data as specified below:
- •AST and ALT < 2.5 x upper limit of normal (ULN)
- •Alk phos < 5.0 x ULN
- •direct bilirubin < 2 x ULN
- •Creatinine < 3.0 x ULN
- •ANC greater than or equal to 750 cells/mm3
- •Platelets > 25,000/mm3
- •Hemoglobin greater than or equal to 7.0g/dL
- •Have life expectancy of at least 3 months
- •Have ECOG performance status of 0, 1, or 2
- •Women and men of child bearing potential must agree to use effective barrier contraceptive methods during study.
- •Have the ability to understand the reuirements of the study, provide written informed consent, abide to study restrictions, and agree to return for the required assessments.
Exclusion Criteria
- •Be pregnant or nursing.
- •Have any condition that is likely to detrimentally affect regular follow up.
- •Have a history of myocardial infarction within the last 3 months, angina pectoris/angina equivalent in the last 3 months, or uncontrolled congestive heart failure.
- •Have an active infection
- •Have had major surgery within 21 days of starting 2ME2 administration
- •Have additional uncontrolled serious medical or psychiatric illness
- •have had any active cancer in addition to the MM within the last 5 years (excluding superficial skin cancer)
- •Have uncontrolled or untreated active bleeding or thrombotic disorder.
Arms & Interventions
1
Experimental
Open label, oral administration of 2ME2
Intervention: 2-methoxyestradiol (Drug)
Outcomes
Primary Outcomes
To determine tumor response of 2ME2 administered orally by evaluation of objective responses in patients with plateau phase or relapsed multiple myeloma
Time Frame: At least yearly
Secondary Outcomes
- To assess the safety and tolerability of 2ME2 administered orally by evaluation of the frequency, severity, and duration of treatment-emergent adverse events in patients with plateau phase or relapsed multiple myeloma(As reported)
- To determine the minimum 2ME2 levels achieved in plasma following daily oral administration in patients with plateau phase or relapsed multiple myeloma(At least yearly)
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Recruiting
Phase 2
A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast CancerTriple-Negative Breast CancerNCT06492005Mabwell (Shanghai) Bioscience Co., Ltd.160
Completed
Phase 2
Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion in Patients With Ovarian CancerOvarian CancerNCT00400348CASI Pharmaceuticals, Inc.18
Terminated
Phase 2
Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other CausalitiesPrimary Familial Dilated CardiomyopathyNCT04572893Bristol-Myers Squibb41
Completed
Phase 2
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non Small Cell Lung Cancer.Non Small Cell Lung CancerNCT00160043Bayer112
Terminated
Phase 1
A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)Relapsed/Refractory Peripheral T-cell LymphomaNCT05403450Taiho Oncology, Inc.33